Optimal management of prostate cancer with lethal biology - State-of-the-art local therapy

Asian Journal of Andrology

Volumn 17, Issue 6, 2015, Pages 888-891

  Chapin, Brian F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; DISEASE SPECIFIC SURVIVAL; GENE MUTATION; GENERAL PRACTICE; HIGH RISK PATIENT; HISTOLOGY; HUMAN; INFLAMMATORY BOWEL DISEASE; INTERMETHOD COMPARISON; LONG TERM ANDROGEN SUPPRESSION; LOWER URINARY TRACT SYMPTOM; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PATIENT; PELVIS; PROSTATE CANCER; RADIATION DOSE; REVIEW; SURVIVAL; TREATMENT OUTCOME; ADENOCARCINOMA; MALE; PATHOLOGY; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY;

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY;

EID: 84946217842     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.156855     Document Type: Review

References (55)

1. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, et al. Long?term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000; 164: 101-5.
2. Carver BS, Bianco FJ Jr, Scardino PT, Eastham JA. Long?term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 2006; 176: 564-8.
3. Connolly SS, Cathcart PJ, Gilmore P, Kerger M, Crowe H, et al. Robotic radical prostatectomy as the initial step in multimodal therapy for men with high?risk localised prostate cancer: initial experience of 160 men. BJU Int 2012; 109: 752-9.
4. Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H. Outcome of surgery for clinical unilateral T3a prostate cancer: a single?institution experience. Eur Urol 2007; 51: 121-8; discussion 128-9.
5. Meng MV, Elkin EP, Latini DM, Duchane J, Carroll PR. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol 2005; 173: 1557-61.
6. Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, et al. Long?term survival after radical prostatectomy versus external?beam radiotherapy for patients with high?risk prostate cancer. Cancer 2011; 117: 2883-91.
7. Zelefsky MJ, Eastham JA, Cronin AM, Fuks Z, Zhang Z, et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 2010; 28: 1508-13.
8. Kibel AS, Ciezki JP, Klein EA, Reddy CA, Lubahn JD, et al. Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol 2012; 187: 1259-65.
9. Tewari A, Divine G, Chang P, Shemtov MM, Milowsky M, et al. Long?term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy-a propensity scoring approach. J Urol 2007; 177: 911-5.
10. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74.
11. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk?adjusted mortality outcomes after primary surgery, radiotherapy, or androgen?deprivation therapy for localized prostate cancer. Cancer 2010; 116: 5226-34.
12. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, et al. External irradiation with or without long?term androgen suppression for prostate cancer with high metastatic risk: 10?year results of an EORTC randomised study. Lancet Oncol 2010; 11: 1066-73.
13. Mottet N, Peneau M, Mazeron JJ, Molinie V, Richaud P. Addition of radiotherapy to long?term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol 2012; 62: 213-9.
14. Warde P, Mason M, Ding K, Kirkbride P, Brundage M, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011; 378: 2104-11.
15. Berglund RK, Jones JS, Ulchaker JC, Fergany A, Gill I, et al. Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis. Urology 2006; 67: 1253-6.
16. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010; 76 3 Suppl: S10-9.
17. Willett CG, Ooi CJ, Zietman AL, Menon V, Goldberg S, et al. Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms. Int J Radiat Oncol Biol Phys 2000; 46: 995-8.
18. Pai HH, Keyes M, Morris WJ, Christie J. Toxicity after (125)I prostate brachytherapy in patients with inflammatory bowel disease. Brachytherapy 2013; 12: 126-33.
19. Peters CA, Cesaretti JA, Stone NN, Stock RG. Low?dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease. Int J Radiat Oncol Biol Phys 2006; 66: 424-9.
20. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549-57; discussion 1564.
21. Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, et al. Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol 2011; 186: 865-72.
22. Aizer AA, Anderson NS, Oh SC, Yu JB, McKeon AM, et al. The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity?modulated radiation therapy. Int J Radiat Oncol Biol Phys 2011; 79: 379-84.
23. Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, et al. Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70: 83-9.
24. Gelblum DY, Potters L, Ashley R, Waldbaum R, Wang XH, et al. Urinary morbidity following ultrasound?guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 1999; 45: 59-67.
25. Slova D, Lepor H. The short?term and long?term effects of radical prostatectomy on lower urinary tract symptoms. J Urol 2007; 178: 2397-400; discussion 2400-1.
26. Sanda MG. Urinary obstructive problems exposed but hormonal health?related quality?of?life concerns eschewed in prostate cancer quality?of?life study. J Clin Oncol 2010; 28: 4667-8.
27. Pardo Y, Guedea F, Aguiló F, Fernández P, Macías V, et al. Quality?of?life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol 2010; 28: 4687-96.
28. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, et al. Quality of life and satisfaction with outcome among prostate?cancer survivors. N Engl J Med 2008; 358: 1250-61.
29. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300.
30. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516-27.
31. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, et al. Ten?year follow?up of radiation therapy oncology group protocol 92?02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26: 2497-504.
32. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby?Hagino ED, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177: 2106-31.
33. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71.
34. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, et al. Prostate cancer, version 2.2014. J Natl Compr Canc Netw 2014; 12: 686-718.
35. Herr HW, O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000; 163: 1743-6.
36. van Andel G, Kurth KH. The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer. Eur Urol 2003; 44: 209-14.
37. Alibhai SM, Breunis H, Timilshina N, Johnston C, Tomlinson G, et al. Impact of androgen?deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol 2010; 28: 5038-45.
38. Smith MR, Lee H, McGovern F, Fallon MA, Goode M, et al. Metabolic changes during gonadotropin?releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008; 112: 2188-94.
39. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol official J Am Soc Clin Oncol 2006; 24: 4448-56.
40. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long?term followup of a randomized clinical trial. J Urol 2009; 181: 956-62.
41. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, et al. European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-8.
42. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate?specific antigen: ARO 96?02/AUO AP 09/95. J Clin Oncol 2009; 27: 2924-30.
43. Yuh B, Ruel N, Muldrew S, Mejia R, Novara G, et al. Complications and outcomes of salvage robot?assisted radical prostatectomy: a single?institution experience. BJU Int 2014; 113: 769-76.
44. Sanderson KM, Penson DF, Cai J, Groshen S, Stein JP, et al. Salvage radical prostatectomy: quality of life outcomes and long?term oncological control of radiorecurrent prostate cancer. J Urol 2006; 176: 2025-31.
45. Chade DC, Shariat SF, Cronin AM, Savage CJ, Karnes RJ, et al. Salvage radical prostatectomy for radi a tion?recurrent prostate cancer: a multi?institutional collaboration. Eur Urol 2011; 60: 205-10.
46. Berrington de Gonzalez A, Curtis RE, Kry SF, Gilbert E, Lamart S, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 2011; 12: 353-60.
47. Spahn M, Joniau S, Gontero P, Fieuws S, Marchioro G, et al. Outcome predictors of radical prostatectomy in patients with prostate?specific antigen greater than 20 ng/ml: a European multi?institutional study of 712 patients. Eur Urol 2010; 58: 1-7; discussion 10-1.
48. Weiner AB, Patel SG, Richards KA, Szmulewitz RZ, Eggener SE. Population?based analysis of treatment modalities and survival for clinically localized small?cell carcinoma of the prostate. Prostate Cancer Prostatic Dis 2014; 17: 286-91.
49. Morgan TM, Welty CJ, Vakar?Lopez F, Lin DW, Wright JL. Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen. J Urol 2010; 184: 2303-7.
50. Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaoglu F, et al. Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. Cancer 2009; 115: 2872-80.
51. Hansel DE, Epstein JI. Sarcomatoid carcinoma of the prostate: a study of 42 cases. Am J Surg Pathol 2006; 30: 1316-21.
52. Langan RC, Lagisetty KH, Atay S, Pandalai P, Stojadinovic A, et al. Surgery for Li Fraumeni syndrome: pushing the limits of surgical oncology. Am J Clin Oncol 2015; 38: 98-102.
53. Heymann S, Delaloge S, Rahal A, Caron O, Frebourg T, et al. Radio?induced malignancies after breast cancer postoperative radiotherapy in patients with Li?Fraumeni syndrome. Radiat Oncol 2010; 5: 104.
54. Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol 2014; 66: 489-99.
55. Madsen LT, Kuban DA, Choi S, Davis JW, Kim J, et al. Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic. J Natl Compr Canc Netw 2014; 12: 993-8.